Find your next paid study

University of New MexicoNCT06115265

Locally Advanced Renal Cell Carcinoma

A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)

All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 w…

Implementation Models for Blood Pressure Monitoring in Pregnancy and Postpartum: Connected MOM Plus

Quality improvement (QI) initiative to improve uptake and utilization of Connected MOM, particularly among those with limited access to health care

Maternal Health CareHypertensive Disorder of Pregnancy

Tulane UniversityNCT07691541

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) af…

Breast Neoplasms

Eli Lilly and CompanyNCT07287098

~$10 – $7,500

Observational

A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating the Efficacy of Multiple Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers.

The goal of this clinical trial is to learn if using perinatal tissue allografts improves healing of chronic, non-healing foot ulcers in diabetic patients. Th…

Diabetic Foot Ulcer

Samaritan BiologicsNCT06437028

~$10 – $7,500

Observational Study of Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape. It is caused by a genetic mutation in the hemoglobin gene. People with SCD are…

Sickle Cell Disease

National Institutes of Health Clinical Center (CC)NCT05170412

~$10 – $675

Observational

Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose surv…

Cardiac Arrest, Out-Of-HospitalHypothermia, InducedHypoxia-Ischemia, Brain

University of MichiganNCT05376267

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment option…

Metastic Thyroid Cancer

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT04927416

~$10 – $5,625

Observational

The Gut Microbiome, Metabolome and Salt-Sensitivity of Blood Pressure

The goal of this interventional study is to learn if elevated Na+ alters the gut microbiota and is associated with altered metabolism, inflammation and salt se…

Salt-sensitivity of Blood Pressure

Vanderbilt University Medical CenterNCT07790900

Metabolic Dysfunction-associated Steatohepatitis

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a THRβ Agonist (ECC4703), an SSAO Inhibitor (ECC0509), and Their Combination in Adults With Presumed MASH

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and …

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjug…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

National Cancer Institute (NCI)NCT06311214

~$10 – $5,625

Phase 1

Efficacy of Topical Ruxolitinib in Acute Skin GVHD: A Pilot Study

The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD)…

Acute Skin Graft Versus Host Disease (GVHD)